IAP

AT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP).

LCL161 is an orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic activity.

Birinapant, also known as TL32711, is a synthetic small molecule and peptido mimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity.

Embelin is a cell-permeable benzoquinone compound that exhibits antitumor properties.

Apoptosis Inhibitor is a cell-permeable inhibitor of apoptosis induction.

GDC-0152 is a second mitochondrial activator of caspases (Smac) mimetic inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity.

BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.

SM-164 is a potent cell-permeable and bivalent Smac mimetic which bind to a XIAP protein with a Ki value of 0.56 nM, and binds to cIAP-1 and cIAP-2 proteins with Ki values of 0.31 and 1.1 nM, respectively.

ASTX660 is an orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptoticctivities. 1799328-86-1 (free base) 1799328-50-9 (HCl) 1799328-90-7 (mesylate) 1799328-88-3 (sulfate)

MV1 is an antagonist of IAP (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand.

CUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.

AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC50s of 15, 21, and 15 nM, respectively.

FL118 is an inhibitor of human survivin expression, activating tumor suppressor p53 as a novel MOA in p53 wild-type cancer cells.

CST626 (Compound 9) is a pan-IAP degrader PROTAC that targets and degrades inhibitor of apoptosis proteins XIAP, cIAP1, and cIAP2 in MM.1S cells, with DC₅₀ values of 0.7 nM, 2.4 nM, and 6.2 nM, respectively.

Dasminapant is a bivalent SMAC mimetic that functions as an inhibitor of inhibitor of apoptosis proteins (IAPs), specifically targeting XIAP, cIAP-1, cIAP-2, and ML-IAP. This compound induces the degradation of cIAP-1 and XIAP, resulting in the activation of caspase-3 and subsequent PARP cleavage, ultimately leading to programmed cell death (apoptosis). Dasminapant is valuable in research applications concerning hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma, providing insights into novel therapeutic strategies.